[1]程镇,石瑞敏,王跃辉,等.前列腺癌患者血清EPCA-2、AGR2、SREBP-1水平变化及检测意义[J].陕西医学杂志,2025,54(11):1542-1546.[doi:DOI:10.3969/j.issn.1000-7377.2025.11.020]
　CHENG Zhen,SHI Ruimin,WANG Yuehui,et al.Changes in serum EPCA-2,AGR2,SREBP-1 levels in prostate cancer patients and their detection significance[J].,2025,54(11):1542-1546.[doi:DOI:10.3969/j.issn.1000-7377.2025.11.020]
点击复制

前列腺癌患者血清EPCA-2、AGR2、SREBP-1水平变化及检测意义

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年11期
页码:
1542-1546
栏目:
临床检验
出版日期:
2025-11-05

文章信息/Info

Title:
Changes in serum EPCA-2,AGR2,SREBP-1 levels in prostate cancer patients and their detection significance
作者:
程镇1; 石瑞敏1; 王跃辉1; 刘肖腾1; 孙文东2
（1.聊城市第二人民医院泌尿外科，山东 聊城 252600；2.山东大学齐鲁第二医院泌尿外科，山东 济南 250002）
Author(s):
CHENG Zhen1; SHI Ruimin1; WANG Yuehui1; LIU Xiaoteng1; SUN Wendong2
(1.Department of Urology,the Second People’s Hospital of Liaocheng,Liaocheng 252600,China；2.Department of Urology,Qilu Second Hospital of Shandong University,Jinan 250002,China)
关键词:
前列腺癌; 早期前列腺癌抗原-2; 前梯度蛋白2; 固醇调节元件结合蛋白-1; 预后; 影响因素
Keywords:
Prostate cancer; EPCA-2; AGR2; SREBP-1; Prognosis; Influencing factors
分类号:
R 737.25
DOI:
DOI:10.3969/j.issn.1000-7377.2025.11.020
文献标志码:
A
摘要:
目的：探讨前列腺癌（PCa）患者血清早期前列腺癌抗原-2（EPCA-2）、前梯度蛋白2（AGR2）、固醇调节元件结合蛋白-1（SREBP-1）水平变化及检测意义。方法：选取184例接受PCa根治术的PCa患者（PCa组），另选150例同期健康者（对照组）。随访患者3年，根据是否出现PCa相关死亡、肿瘤复发或术后前列腺特异性抗原（PSA）降低将患者分为预后不良组（44例）和预后良好组（140例）。比较各组血清EPCA-2、AGR2、SREBP-1水平。采用多因素Logistic回归分析PCa患者预后不良的影响因素。评估多因素Logistic回归模型中自变量的共线性程度采用方差膨胀因子（VIF）进行分析。通过受试者工作特征（ROC）曲线分析血清EPCA-2、AGR2、SREBP-1对PCa患者预后不良的预测价值。结果：PCa组血清EPCA-2、AGR2、SREBP-1水平较对照组升高（均P＜0.05）。与预后良好组比较，预后不良组患者淋巴结转移、TNM分期Ⅲ-Ⅳ期、肿瘤低分化、Gleason评分(GS)≥7分、手术切缘阳性比例较高（均P＜0.05）。与预后良好组比较，预后不良组血清EPCA-2、AGR2、SREBP-1水平升高（均P＜0.05）。PCa患者预后不良的独立影响因素为手术切缘、肿瘤分化程度、TNM分期、GS评分、淋巴结转移及血清EPCA-2、AGR2、SREBP-1（均P<0.05），且各变量VIF值均＜5。血清EPCA-2、AGR2、SREBP-1单独及联合预测PCa患者预后不良的曲线下面积（AUC）分别为0.711、0.842、0.783、0.968，且联合预测AUC最高（均P＜0.05）。结论：PCa患者血清EPCA-2、AGR2、SREBP-1水平升高，与患者预后有关，三者联合检测对患者预后不良具有一定预测价值。
Abstract:
Objective:To investigate the changes in serum levels of early prostate cancer antigen-2 (EPCA-2),anterior gradient 2 (AGR2),and sterol regulatory element binding protein-1 (SREBP-1) in patients with prostate cancer (PCa) and the significance of their detection.Methods：A total of 184 patients who underwent radical prostatectomy for PCa (PCa group) and 150 healthy individuals (control group) during the same period were selected.The patients were followed up for 3 years and were divided into poor prognosis group (44 cases) and good prognosis group (140 cases) based on whether they experienced PCa-related death,tumor recurrence,or a decrease in postoperative prostate-specific antigen (PSA).The serum levels of EPCA-2,AGR2 and SREBP-1 were compared among the groups.Multivariate logistic regression analysis was used to identify the influencing factors of poor prognosis in PCa patients.The degree of collinearity among the independent variables in the multivariate logistic regression model was assessed using the variance inflation factor (VIF).The predictive value of serum EPCA-2,AGR2 and SREBP-1 for poor prognosis in PCa patients was analyzed using ROC curves.Results:The serum levels of EPCA-2,AGR2 and SREBP-1 in the PCa group were significantly higher than those in the control group (all P<0.05).Compared with the good prognosis group,the poor prognosis group had a higher proportion of lymph node metastasis,TNM stage Ⅲ-Ⅳ,poorly differentiated tumors,Gleason Score (GS)≥7,and positive surgical margins (all P<0.05).The serum levels of EPCA-2,AGR2 and SREBP-1 were also higher in the poor prognosis group than in the good prognosis group (all P<0.05).The independent influencing factors for poor prognosis in PCa patients included surgical margins,tumor differentiation,TNM stage,GS score,lymph node metastasis,and serum levels of EPCA-2,AGR2 and SREBP-1(all P<0.05),with all VIF values being less than 5.The AUC for predicting poor prognosis in PCa patients using serum EPCA-2,AGR2,SREBP-1 alone and in combination were 0.711,0.842,0.783 and 0.968,respectively,with the highest AUC for combined prediction (all P<0.05).Conclusion:Elevated serum levels of EPCA-2,AGR2 and SREBP-1 in PCa patients are associated with poor prognosis,and combined detection of these markers has a certain predictive value for poor prognosis.

参考文献/References:

[1]程树林,杜中波,黄静,等.长链非编码RNA LINC00926调控微小RNA-331-3p对前列腺癌细胞增殖和迁移的影响[J].陕西医学杂志,2025,54(2):170-174,180.
[2]张丽鹏,钱卫红,丁献凡,等.老年前列腺癌患者前列腺根治术后影响尿控恢复状况的相关因素[J].中华老年多器官疾病杂志,2024,23(1):27-31.
[3]代佳,韩卫军,贺林,等.术前血清磷酸甘油酸激酶1、髓样相关蛋白8/14水平与前列腺癌根治术患者预后和生存情况相关性研究[J].陕西医学杂志,2022,51(11):1389-1392,1411.
[4]李月峰,王伟,张珑,等.mp-MRI定量参数联合血清EPCA-2、PSA表达水平检测对前列腺癌包膜侵犯的诊断价值[J].西部医学,2025,37(2):262-266.
[5]柯楠,刘凯,陈娇,等.改良PI-RADS评分联合血清AGR2、sTim-3水平对前列腺癌的诊断价值[J].中国性科学,2025,34(1):40-44.
[6]时景伟,陈欢,崔蕊,等.前梯度蛋白2与血管内皮生长因子C在前列腺癌组织的表达及其临床意义[J].中华实验外科杂志,2018,35(4):785-786.
[7]姜华,张贺,江松松.固醇调节元件结合蛋白1促进前列腺癌细胞增殖和侵袭[J].基础医学与临床,2025,45(2):189-196.
[8]齐笑笑,吕雪娇,郑若男,等.基于SREBP-1探讨水飞蓟宾对曲普瑞林抑制前列腺癌LNCaP细胞增殖、迁移和侵袭的影响[J].国际免疫学杂志,2025,48(2):122-130.
[9]那彦群,李鸣.前列腺癌临床诊断与治疗:从指南到临床[M].北京:人民卫生出版社,2011:206-209.
[10]李书剑,黄宝生.扶正抑瘤汤对经尿道前列腺等离子电切术后晚期前列腺癌患者预后的影响[J].陕西中医,2021,42(1):68-70,74.
[11]刘婷婷,王晓辉,王洪兴,等.动态增强磁共振成像定量参数联合表观扩散系数值对外周带前列腺癌的诊断价值研究[J].临床误诊误治,2024,37(13):71-76.
[12]王贵华,杨长命,徐卉卉,等.放射性125I粒子植入术联合内分泌疗法治疗前列腺癌的疗效评价[J].实用心脑肺血管病杂志,2016,24(4):86.
[13]孙鹤云.长链非编码RNA SNHG3调控miR-326/PAX5信号促进前列腺癌增殖侵袭的机制研究[D].苏州:苏州大学,2023.
[14]赵燕,邹磊,陈敬玉,等.超声造影参数、SII及NLR水平对前列腺癌根治术预后评估的价值[J].中国医师杂志,2024,26(12):1830-1834.
[15]WANG G,ZHAO D,SPRING D J,et al.Genetics and biology of prostate cancer[J].Genes Dev,2018,32(17-18):1105-1140.
[16]张涛,宋新浩,王小兵,等.经直肠超声联合血清EPCA-2、hK2对前列腺癌的早期诊断价值研究[J].成都医学院学报,2024,19(4):633-636.
[17]李坤,郑钧泽,李瑞东,等.磁共振成像联合血清前列腺特异抗原、上皮钙黏蛋白、早期前列腺癌抗原-2诊断前列腺癌的临床价值探讨[J].现代生物医学进展,2022,22(14):2763-2767.
[18]苏静静,鲁文权,绍宝儿,等.磁共振成像联合血清TPSA、FPSA/TPSA、EPCA-2对前列腺癌的诊断价值[J].中国性科学,2020,29(5):4-8.
[19]崔胜宏,马秀梅,闫红梅,等.DCE-MRI联合血清sE-cadherin、AGR2检测诊断前列腺癌的临床价值[J].现代肿瘤医学,2021,29(14):2490-2496.
[20]顾安琪,梅迪,黄健.血清AGR2、PGK1、MRP8/14表达情况与前列腺癌患者术后疗效评估及生存情况的相关性[J].临床血液学杂志,2021,34(2):121-126.
[21]RODRGUEZ-BLANCO G,ZENEYEDPOUR L,DUIJVESZ D,et al.Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer[J].Oncotarget,2018,9(92):36444-36456.
[22]WAMBACH M,MONTANI M,RUNZ J,et al.Clinical implications of AGR2 in primary prostate cancer:Results from a large-scale study[J].APMIS,2024,132(4):256-266.
[23]TANG D,HE J,DAI Y,et al.Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer[J].Cancer Gene Ther,2022,29(5):543-557.
[24]LI L,HUA L,FAN H,et al.Interplay of PKD3 with SREBP1 promotes cell growth via upregulating lipogenesis in prostate cancer cells[J].J Cancer,2019,10(25):6395-6404.
[25]郑永波.SREBP-1与AR调控脂质代谢和恩扎卢胺药物敏感性对去势抵抗性前列腺癌的影响研究[D].重庆:重庆医科大学,2023.
[26]LI B,CHENG B,HUANG H,et al.Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer[J].Int J Biol Sci,2024,20(12):4635-4653.

相似文献/References:

[1]杜丽娜,康 峰△,苏燕胜,等.围术期常规干预联合下腹部局部热敷在前列腺癌电切术后排尿困难患者中的应用研究*[J].陕西医学杂志,2019,(6):784.
[2]雷 普,卢红梅,卜小斌,等.新型内分泌联合化疗治疗高危前列腺癌临床研究[J].陕西医学杂志,2021,50(4):454.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.018]
[3]贺 煜,常莉莉,潘治军.SPECT/CT联合血清游离前列腺特异性抗原/总前列腺特异性抗原检查对前列腺癌及骨转移的诊断价值[J].陕西医学杂志,2021,50(9):1102.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.015]
　HE Yu,CHANG Lili,PAN Zhijun.Diagnostic value of SPECT/CT combined with serum fPSA/tPSA in prostate cancer and bone metastasis[J].,2021,50(11):1102.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.015]
[4]代 佳,韩卫军,贺 林,等.术前血清磷酸甘油酸激酶1、髓样相关蛋白8/14水平与前列腺癌根治术患者预后和生存情况相关性研究[J].陕西医学杂志,2022,51(11):1389.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.016]
　DAI Jia,HAN Weijun,HE Lin,et al.Correlation between preoperative serum phosphoglycerate kinase 1,myeloid-associated protein 8/14 levels and prognosis and survival of patients undergoing radical prostatectomy[J].,2022,51(11):1389.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.016]
[5]王小禹,周 宁,黄 芩,等.蛋白精氨酸甲基转移酶5在前列腺癌组织中的表达及其与患者临床病理特征的关系[J].陕西医学杂志,2023,52(11):1602.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.033]
　WANG Xiaoyu,ZHOU Ning,HUANG Qin,et al.Expression of arginine methyltransferase PRMT5 in prostate cancer tissues and its relationship with clinicopathological features of patients[J].,2023,52(11):1602.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.033]
[6]钟 倩,吴洪瀚,吴恒鹏,等.前列腺癌转基因动物模型研究进展[J].陕西医学杂志,2023,52(12):1778.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.033]
　ZHONG Qian,WU Honghan,WU Hengpeng,et al.Research progress in transgenic animal models of prostate cancer[J].,2023,52(11):1778.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.033]
[7]马 俊,邵恩明,包 娟,等.长链非编码RNA LINC02587对前列腺癌细胞增殖和侵袭的影响及机制实验研究[J].陕西医学杂志,2024,(11):1443.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.001]
　MA Jun,SHAO Enming,BAO Juan,et al.Effect and mechanism of long non-coding RNA LINC02587 on the proliferation and invasion of prostate cancer cells[J].,2024,(11):1443.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.001]
[8]程树林,杜中波,黄 静,等.长链非编码RNA LINC00926调控微小RNA-331-3p对前列腺癌细胞增殖和迁移的影响[J].陕西医学杂志,2025,54(2):170.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.005]
　CHENG Shulin,DU Zhongbo,HUANG Jing,et al.Effect of lncRNA LINC00926 on the proliferation and migration of prostate cancer cells by regulating miR-331-3p[J].,2025,54(11):170.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.005]
[9]陈霖,郑建民.DCE-MRI参数联合血清SGK2、ACTN4对前列腺癌患者预后的预测价值[J].陕西医学杂志,2026,(2):187.[doi:DOI:10.3969/j.issn.1000-7377.2026.02.007]
　CHEN Lin,ZHENG Jianmin.Predictive value of DCE-MRI parameters combined with serum SGK2 and ACTN4 for the prognosis of prostate cancer patients[J].,2026,(11):187.[doi:DOI:10.3969/j.issn.1000-7377.2026.02.007]

备注/Memo

备注/Memo:
山东省医药卫生科技发展计划项目（2019WS102）
更新日期/Last Update: 2025-11-04